Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disorder. 1 It is characterized by synovial inflammation, joint swelling, tenderness, and stiffness. This can lead to bone erosion, cartilage damage, and joint destruction that result in substantial disability.
RA is a disease with serious financial and health impact. Approximately 1.5 million adults in the USA are diagnosed with RA. 2 From 1997 to 2005, annual medical care expenditures among US adults with arthritis increased by $100 billion. 3 In 2008 alone, the adjusted average annual total expenditure per patient for RA in the USA was $13,012. 4 Additionally, in a retrospective database analysis, societal costs for RA in the USA, including intangible costs, were estimated to be $39.2 billion. 5 Active RA 
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Fischer and Rapoport is associated with excess morbidity, including cardiovascular disease, type 2 diabetes, and malignancies (lymphoma). [6] [7] [8] The primary goal of therapy is to manage inflammation and disease activity. 1, 9 Treatment options for RA include the following: glucocorticoids, which decrease inflammation and reduce immune system activity, but are limited by a high side effect profile; conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), which slow the progression of joint damage by influencing the immune system; and biologic DMARDs (bDMARDs), which are produced by recombinant DNA technology and generally target cytokines, their receptors, or other cell surface molecules. 1, 10 Despite the availability of csDMARDs and bDMARDs, RA does not respond to treatment in many patients and remains inadequately controlled. 9 Repository corticotropin injection (RCI), a highly purified porcine analog of adrenocorticotropic hormone (ACTH), 11 may benefit patients with refractory RA. Similar to ACTH, RCI stimulates the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weak androgenic substances. ACTH is a member of the melanocortin family of peptides. 12 ACTH not only exerts steroidogenic effects by interacting with the melanocortin 2 receptor (MC 2 R) in the adrenal cortex, but also has nonsteroidogenic effects. This is apparent in its interactions with receptors found on immune cells, osteoblasts, osteoclasts, and cells of the synovium. [12] [13] [14] It has been shown that ACTH binds to all five known melanocortin receptors (MC 1-5 R), which suggests ACTH may possess anti-inflammatory and immunomodulatory effects by activating the other MCRs in addition to MC 2 R.
Through these pathways, RCI may ameliorate disease symptoms. Even short treatment with RCI may impact disease progression as it has been shown that a 5-day course of intramuscular or subcutaneous RCI improved the symptoms associated with acute exacerbations of multiple sclerosis. 15 A claims-based analysis of patients with RA, systemic lupus erythematosus, dermatomyositis, and polymyositis demonstrated that RCI use may be linked to a significant decrease in corticosteroid requirements. 16 Based on these data, it is possible that RCI in combination with csDMARDs and bDMARDs may provide relief from RA and ameliorate acute exacerbations of RA in patients with disease that is inadequately controlled by these therapeutic agents alone.
Patients and methods
The objective of this study was to assess the efficacy and safety of adjunctive RCI treatment in patients with active RA who have had an inadequate response to csDMARDs and at least three bDMARDs (including one tumor necrosis factor inhibitor). This was a 12-week observational, prospective, multicenter, open-label study conducted in two private practices in the USA. Patients were screened for eligibility within 5 days prior to study initiation. Patients were eligible if they had active disease, which was defined as ≥6 swollen joints, ≥6 tender joints, and C-reactive protein (CRP) levels and/or erythrocyte sedimentation rate ≥1.2 times the upper limit of normal. Patients were taking stable doses of csDMARDs and bDMARDs for 3 months and stable doses of nonsteroidal anti-inflammatory drugs, prednisone, or equivalent dose of corticosteroid (≥7.5 mg/day), and analgesics for 28 days prior to screening.
A total of 40 U RCI (80 USP units/mL) was administered subcutaneously daily for 7 days as adjunctive therapy. After 1 week, doses were adjusted based on response. An adequate response was defined as >1.2 point reduction in the Disease Activity Score 28 using CRP (DAS28-CRP). 17 If an adequate response was achieved, patients were given 40 U RCI twice weekly through Week 12. If the response was inadequate, patients received 80 U RCI daily for 7 days, followed by 80 U twice weekly through Week 12.
The primary endpoint was an adequate response of >1.2 point reduction in DAS28-CRP at Week 12 compared with baseline. Secondary endpoints included a decrease in Health Assessment Questionnaire-Disease Index (HAQ-DI) 18 and an increase in Functional Assessment of Chronic Illness Therapy (FACIT) 19 scores. Cortisol levels were also assessed at study visits.
The nature, incidence, and severity of adverse events (AEs) and serious adverse events (SAEs) were monitored after administration of RCI and throughout the study. AEs were documented, evaluated, and treated by the principal investigator according to a standard of care. The AEs were also reported to the Institutional Review Board (IRB) and Mallinckrodt Pharmaceuticals (the manufacturer of RCI) within 5 business days. All SAEs were reported to the IRB and Mallinckrodt within 24 h.
Written informed consent was obtained from all patients prior to study initiation. IRB approval was obtained at each investigator's institution (Dr Fischer: Sturdy Memorial Hospital Institutional Review Board, Attleboro MA; Dr Rapoport: Shulman IRB, Research Triangle Park, NC). This study is registered at ClinicalTrials.gov (NCT02434757).
Results
A total of nine patients with active RA were maintained on stable doses of csDMARDs, bDMARDs, and prednisone 
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RCI for RA resistant to biologic therapies (minimum of 7.5 mg daily). The patients (four women and five men; age range 44-62 years) had an average RA history of 11.7 years (Table 1) . After 1 week of therapy, five of the nine patients had improvements in DAS28-CRP and continued to receive 40 U RCI (patients 2, 3, 6, 8, and 9), while the remaining four patients were dose escalated to 80 U RCI (patients 1, 4, 5, and 7). Six of the nine patients (patients 2, 3, 5, 6, 8, and 9) met the primary endpoint (Figure 1) , including all five in the 40 U RCI group and one from the 80 U RCI group. Two patients dropped out of the study due to inadequate response (patients 1 and 7) . The mean DAS28-CRP improvement at 12 weeks (change in DAS28-CRP from baseline to Week 12) among patients on 40 U of therapy (−1.994) was numerically greater than that in patients increasing their dose to 80 U (−1.635; Figure 2 ).
There were also improvements in secondary endpoints. Both FACIT and HAQ-DI changes were evident as early as Week 1 and improvements remained consistent through Week 12 ( Figure 2 ). Four of the nine patients (patients 2, 5, 6, and 8) maintained improvement in both HAQ-DI and FACIT scores at Week 12 compared with baseline, while one (patient 9) maintained improvement in HAQ-DI score only (Figure 1) .
Cortisol levels did not increase at Week 1, even with daily dosing of RCI (Table 2) ; no clear association was noted between cortisol levels and RCI response. Of the four patients who had an RCI dose increase to 80 U, three had cortisol data available beyond Week 1, two of whom had a prominent increase in cortisol levels.
No SAEs occurred. AEs recorded in the study included cushingoid features (n=2), mild hyperglycemia (n=1), herpes zoster (n=1), and pedal edema (n=1).
Discussion
Our study reinforces the effectiveness of RCI treatment in patients with active RA. 20 Of the nine patients treated with RCI, five responded to 40 U daily for 1 week and did not need a dose increase (patients 2, 3, 6, 8, and 9). One patient in the 80 U group had clinically significant improvement (patient 5). Four of the five patients on 40 U RCI showed improvement in HAQ-DI score (patients 2, 6, 8, and 9) and one showed no change (patient 3). Of the four patients on 80 U RCI, one showed improvement (patient 5), two dropped out (patients 1 and 7), and one patient's HAQ-DI score declined (patient 4). At Week 12, all but one patient on 40 U RCI showed improvement in FACIT (patient 9). Of the patients taking 80 U RCI, only one showed improvement in FACIT score (patient 5).
Our study -although not double blinded or placebo controlled -is one of the few prospective studies on the effect 
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RCI for RA resistant to biologic therapies in a majority of patients. Perhaps the mechanism of action of RCI is not dependent on dosing as long as a minimum threshold is met. These patients had active, severe RA and were unresponsive to three bDMARDs; for this reason, they were maintained on a minimum prednisone dose of 7.5 mg/day. Cortisol levels did not increase after daily dosing of RCI (Week 1). It is possible that cortisol levels did not increase due to lower doses of RCI not having an affect on the adrenal glands, or because some of the patients were adrenally
Open Access Rheumatology: Research and Reviews 2018:10 submit your manuscript | www.dovepress.com
Dovepress

18
Fischer and Rapoport suppressed. As dose escalation did not reliably decrease disease activity or increase cortisol levels in all patients, this suggests a mechanism of action for RCI besides steroidogenesis. In our study, interpretation of cortisol levels is challenging because patients were maintained on a daily dose of prednisone. Further placebo-controlled studies in patients not receiving prednisone are needed to fully understand the mechanisms of RCI.
Conclusion
RCI produced a clinically meaningful reduction in markers of disease activity, improved quality of life (as assessed by HAQ-DI), and demonstrated a favorable safety profile. Cortisol levels did not seem to correlate with clinical response. Also, 40 U RCI twice weekly is an effective RA treatment as shown by the response rate. The response rate was numerically lower in the 80 U RCI treatment group; however, this may be due to the patients who were dose escalated, representing nonresponders to treatment with RCI. For patients who are refractory to common RA treatment, the response rate to RCI was substantial and shows great promise in this difficult-to-treat population.
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